scholarly journals Validation of a behavioral economic purchase task for assessing drug abuse liability

2018 ◽  
Vol 24 (2) ◽  
pp. 303-314 ◽  
Author(s):  
James MacKillop ◽  
Nicholas I. Goldenson ◽  
Matthew G. Kirkpatrick ◽  
Adam M. Leventhal
Keyword(s):  
Drug Abuse ◽  
Abuse Liability ◽  
Behavioral Economic

Drug abuse liability assessment: Validation of a behavioral sensitization test following oral administration in rats

2011 ◽  
Vol 64 (1) ◽  
pp. e24
Author(s):  
Julie Latour ◽  
Florence Pradier ◽  
Elisabeth Patterson ◽  
Florence Lozano ◽  
Magali Fric-Bordat ◽  
...  
Keyword(s):  
Drug Abuse ◽  
Oral Administration ◽  
Behavioral Sensitization ◽  
Abuse Liability ◽  
Assessment Validation

Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo

1993 ◽  
Vol 8 (4) ◽  
pp. 201-208 ◽  
Author(s):  
D Warot ◽  
E Corruble ◽  
C Payan ◽  
JS Weil ◽  
AJ Puech
Keyword(s):  
Drug Abuse ◽  
Healthy Volunteers ◽  
Subjective Effects ◽  
Abuse Liability ◽  
Healthy Population ◽  
Profile Of Mood States ◽  
Double Blind ◽  
Visual Analog Scales ◽  
History Of ◽  
Addiction Research Center Inventory

SummaryThe subjective, behavioral and physiological effects of modafinil (300 mg PO) a new central adrenergic stimulant, were compared with those of dextroamphetamine (15 mg PO), caffeine (300 mg PO) and placebo in a randomized double-blind cross-over study. Sixteen healthy volunteers participated in the study y: 8 males and 8 females with no history of drug abuse and moderate use of caffeine. Subjective and behavioral effects were studied using the Addiction Research Center Inventory (ARCI), Profile of Mood States (POMS) and Visual Analog Scales before and 1, 2, 4 and 8 h post single oral dosing. Results showed that subjective effects of modafinil (300 mg) differed markedly from those of dextroamphetamine (15 mg). They were close to those produced by caffeine (300 mg). These results indicate that modafinil (300 mg) does not possess amphetamine-like subjective effects in a healthy population. If subjective feelings are related to drug abuse liability, it could be assumed that modafinil, at the dose used in therapeutics, does not possess any abuse liability comparable to amphetamine.

Drug abuse liability assessment: Validation of a spontaneous withdrawal test in rats using a computerized system

2011 ◽  
Vol 64 (1) ◽  
pp. e23
Author(s):  
Julie Latour ◽  
Sebastien Faure ◽  
Florence Pradier ◽  
Elisabeth Patterson ◽  
Florence Lozano ◽  
...  
Keyword(s):  
Drug Abuse ◽  
Abuse Liability ◽  
Assessment Validation ◽  
Spontaneous Withdrawal ◽  
Computerized System
Sign in / Sign up

Export Citation Format

Share Document